New global poll finds unemployment remains the top issue around the world. What Worries the World study finds the majority of people across 26 countries think that their country is on the wrong track — Mexico, South Africa, Brazil, Italy and Hungary being the most concerned.
Ipsos Healthcare, the global healthcare division of Ipsos, has launched the Hidradenitis Suppurativa (HS) Therapy Monitor in the EU5. The HS Monitor, part of Ipsos’ Autoimmune Real World Evidence portfolio, launched in the EU5 in Q2 of 2017, with plans to extend to other markets.
The strong growth potential of emerging economies, such as those within the Association of Southeast Asian Nations (ASEAN), continues to attract attention from global businesses.
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.
With care for older people rising up the policy agenda and generating widespread debate, we invite you to come on July 20 and hear the findings of our research project exploring unmet need for adult social care for older people and discuss the implications with our panel.
New global poll finds unemployment remains the top issue globally. New study finds the majority of people across 26 countries think that their country is on the wrong track — South Africa, Mexico, Brazil, South Korea, Italy and France are the most concerned.
Ipsos Healthcare has extended its syndicated Psoriasis and IBD Therapy Monitors into China. It will also re-launch the Lupus Therapy Monitor in China due to increased client demand
On May 20, please join the Ipsos Healthcare team who’ll be presenting data on key topics in NASH, Oncology, Diabetes and Obesity, as well as exhibiting at the 22nd International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting.
